ArticleFrontiers in artificial intelligence2026
Adaptive Gating and Focal Debiasing for robust few-shot retinal disease classification.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hybrid attention few-shot models are promising for automated retinal disease classification in data-scarce settings, yet two issues persist: static fusion of global and local features, and weak performance on minority classes. We propose Adaptive Gating and Focal Debiasing (AGFD), which adds a Dynamic Attention Gating (DAG) module that learns input-specific weights for global and local attention branches, and replaces cross-entropy with focal loss to shift learning toward hard, underrepresented cases. On ODIR-5K under episodic evaluation, AGFD improves over a strong hybrid-attention baseline across all shot settings, reaching 78.7% accuracy and 76.9% macro-F1 in the 5-shot setting, and 83.2% accuracy at 10-shot. Minority classes benefit most, with +11-15 percentage-point F1 gains for Glaucoma, Cataract, Hypertension, and Other. Gate analysis shows higher global weighting for widespread conditions and higher local weighting for lesion-driven diseases. Coupling adaptive fusion with a debiased objective improves overall accuracy and reliability on underrepresented classes, a step toward more clinically useful screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.